Stefani Spranger on What Every Oncologist Should Know About Immunotherapy

Stefani Spranger, PhD
Published: Wednesday, Oct 19, 2016


Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.
 
Immunotherapy actives the immune system to recognize and then destroy the cancer, says Spranger. The main players in this recognition are CD8-positive T cells. These are the T cells in viral infections that are responsible for killing the infected cells.
 
With cancer, because the body’s own cells are attacking it, the CD8-positive T cells do not know to fight it. Immunotherapy educates the immune system to do this and could possibility be used to fight most of the cancers that are currently out there, says Spanger.
 

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.
 
Immunotherapy actives the immune system to recognize and then destroy the cancer, says Spranger. The main players in this recognition are CD8-positive T cells. These are the T cells in viral infections that are responsible for killing the infected cells.
 
With cancer, because the body’s own cells are attacking it, the CD8-positive T cells do not know to fight it. Immunotherapy educates the immune system to do this and could possibility be used to fight most of the cancers that are currently out there, says Spanger.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x